WO2003000147A1 - Appareil et methode de traitement de maladies des articulations - Google Patents
Appareil et methode de traitement de maladies des articulations Download PDFInfo
- Publication number
- WO2003000147A1 WO2003000147A1 PCT/JP2002/006438 JP0206438W WO03000147A1 WO 2003000147 A1 WO2003000147 A1 WO 2003000147A1 JP 0206438 W JP0206438 W JP 0206438W WO 03000147 A1 WO03000147 A1 WO 03000147A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- mmp
- joint
- ultrasonic
- activity
- joint disease
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N7/00—Ultrasound therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/56—Surgical instruments or methods for treatment of bones or joints; Devices specially adapted therefor
- A61B2017/564—Methods for bone or joint treatment
Definitions
- the present invention relates to an apparatus and a method for treating a joint disease. More specifically, ultrasound is applied to the joint disease site to reduce the activity of matrix metalloprotease (MMP) in synovial fluid in joint disease and to suppress tissue destruction. It is an apparatus and method for improvement.
- MMP matrix metalloprotease
- the major joint diseases include rheumatoid arthritis and osteoarthritis. These joint diseases, although their etiology and pathology vary greatly, are consistent in that they cause inflammation, pain, and dysfunction due to the destruction of articular cartilage, and eventually cause joint dysfunction. Despite the increase in the number of patients, it is effective in ensuring that the disease is completely cured, despite the use of analgesic and anti-inflammatory drugs such as aspirin and indomethacin, and steroids, immunomodulators, and other therapeutic agents for each disease state. At present, there are no remedies.
- Matrix metalloprotease is a protease having a metal ion at its active center, and its involvement in the pathology of joint diseases such as osteoarthritis has been suggested [aiotti et al., Arthroscopy 16, 522-526. (2000), Tanak et al. Semin Arthritis Rheum 27, 392-399 (1998)].
- MMP-1 is also called collagenase 1 and has the action of degrading collagen
- Its involvement in arthrosis has been reported for a long time [Ehrl ioh et al. J Cl in Inves 59, 226-233 '(1977), Pelletier et al. Arthritis Rheum 26, 63-68 (1983)].
- Okada and colleagues also examined the relationship between MMP-3 (stromlysin-1), which has the ability to degrade cartilage matrix aggrecan, and osteoarthritis, the expression rate of MMP-3 positive chondrocytes and the degree of cartilage degeneration.
- MMP-3 stromlysin-1
- MMP-13 is also called collagen 3 and has an action to degrade collagen 'faster than MMP-1, suggesting its involvement in cartilage destruction in osteoarthritis. [M cheH et al. J Cl in Invest 97, 761-768 (1996)]. Furthermore, it has been reported that MMP activity is also increased in synovial fluid of rheumatoid arthritis.
- Such a drug having an MMP activity inhibitory effect on MMP is expected to be used as a therapeutic drug for rheumatoid arthritis, osteoarthritis, etc.
- a method of improving the tissue score in joint disease a method of improving the tissue score by administering an interleukin-1 (IL-11) receptor antagonist [Pel letier et al., US Patent No. 5, 972, 880] It has been known.
- IL-11 interleukin-1
- the present invention is an concealment that reduces the MMP activity of a joint by irradiating an ultrasonic wave to a joint diseased site, and at least one ultrasonic transducer, an ultrasonic transmitter, Equipped with means for attaching the ultrasonic transducer to the joint site, frequency 1.3 to 2 MHz, repetition cycle "100 to 1,00 OHz, burst width 10 to 20 ⁇ 0 ⁇ 5, output
- the purpose of the present invention is to provide a joint disease treatment device which is a means for irradiating an ultrasonic wave of 100 mW / cm 2 (SATA: Spatial Average-Temporal Average).
- the present invention also provides a method for reducing MMP activity, which comprises irradiating a site where matrix metalloprotease (MMP) activity is enhanced with ultrasonic waves.
- MMP matrix metalloprotease
- SATA Spatial Average-Temporal Average, space-time flat
- the present invention provides a method for reducing MMP activity, characterized in that the MMP is MMP-1, MMP-3, and / or MMP-13.
- Figure 1 shows the effect of low power ultrasound on the femoral condyle of the knee, as assessed by the modified Mankinscore method;
- FIG. Data are shown as mean ⁇ standard deviation ⁇ .
- the ⁇ value in ⁇ is the difference between the two groups, the one-sided t-test of Student's vs. JS without 7S results.
- FIG. 2 shows the effect of low-power ultrasound on MMP-1 activity in synovial fluid. Data are shown as mean soil standard deviation ⁇ . The P value in the figure is the result of performing a one-sided t-test without a pair of Student's on the difference between the two groups.
- FIG. 3 shows the effect of low-power ultrasound on MMP-3 activity in synovial fluid. Data are shown as mean soil standard deviation. The P value in the figure is the result of performing a one-tailed t-test without the difference between the two groups and without the Student's pair.
- FIG. 4 shows the effect of low power ultrasound on MMP-13 activity in synovial fluid;
- FIG. Data are shown as mean soil standard error.
- the P furnace in the figure performs the two-group difference, the one-sided test of Student's vs. JS without JS; the result is the result.
- FIG. 5 is an external view of the joint disease treatment device of the present invention.
- FIG. 6 is a schematic flowchart of the joint disease treatment apparatus of the present invention.
- the joint disease treatment apparatus of the present invention is an apparatus for reducing the MMP activity at the position of the 'joint' by ultrasonic irradiation, comprising at least one ultrasonic transducer, an ultrasonic transmitter, and the ultrasonic transducer.
- ultrasonic waves t illuminated comprises mounting means to one joint site refers to low-power ultrasound, such as hardly generate heat. Specifically, it is a low-power ultrasonic wave having a frequency of 1.3 to 2 MHz, a repetition period of 10 to 1,00 OHz, a burst width of 1 to 2000 s, and an output of 1 OOmW / cm 2 (SATA) or less.
- the irradiation method for example, it is preferable to transmit a 20-minute low-power ultrasonic wave pulse to the affected part, and to perform irradiation for a continuous period.
- an ultrasonic output unit SAF HS2000® manufactured by EXogen, USA
- the characteristics of the ultrasonic output were as follows: burst width '200 Ws, frequency 1.5 MHz, 1 kHz repetitive localization, Preferably, the output is 3 OmW / cm 2 .
- the structure of the ultrasonic transmitter and the transducer is as follows. The signal from the ultrasonic transmitter is transmitted to the treatment head module with a built-in transducer through a cable. This is a non-invasive treatment device that irradiates an ultrasonic pulse with the above characteristics close to the patient and percutaneously from outside the body.
- the attachment of the treatment head module to the joints such as the knees and elbows varies depending on the diseased part and the disease state.
- fix the limb with the upper limb and Z or lower limb and make the limb joint perpendicular A joint angle fixing section for fixing in a bent state, and an installation section for an ultrasonic treatment head module, and a module for irradiating an ultrasonic wave to a joint cavity direction of the limb joint and a femoral condyle packing direction.
- An installation section will be provided.
- the contact surface between the treatment head module and the skin is made through an ultrasound-transmitting gel. It is possible to irradiate without ⁇ 9 attenuation.
- the joint disease to which the device for treating a joint disease of the present invention is applied is a disease in which MMP activity is enhanced, such as osteoarthritis, osteochondritis dissecans, 'Osgood Schullat' disease, rheumatoid arthritis and the like. No. In particular, it is preferable to target osteoarthritis and rheumatoid arthritis.
- Such a group model is an animal model of osteoarthritis and was prepared as follows.
- a 0.5 mm groove (group) was made crosswise in the load area of the left hind limb femoral condyle of a beagle dog (female, weight 1 ⁇ -20 kg), and the side knee was treated / £.
- the right hind limb was left untreated. Thereafter, the right hind limb was fixed with a bandage three times a week for 6 hours, and an exercise load was applied to the operated knee to form a group osteoarthritis model.
- the experiment set the following two groups ⁇ .
- Ultrasonic transducers that emit ultrasonic waves with a burst width of 200 s, a frequency of 1.5 MHz, a repetition cycle of 1 kHz, and an output of 3 mW / cm 2 (SATA) as characteristics of ultrasonic output.
- Built-in ultrasonic output 1 nit, equipped with an ultrasonic transmitter, using a treatment device and generating ultrasonic waves, 1 for 20 minutes, every 10 weeks, and said the group osteoarthritis model beagle dog The knee of the left hind limb was irradiated with ultrasound (5 cases in 2 groups).
- the left hind limb was fixed in a bent state at 90 degrees, and irradiated from the medial side of the knee toward the left hind limb femoral condyle loading part in the group direction.
- An ultrasonic transducer was brought into contact with the left hind limb knee via an ultrasonic conductive gel.
- Ultrasonic output unit was attached to the hind limb knee, with no ultrasonic waves generated, for 1 minute for 20 minutes and every 10 weeks (5 cases). After 10 weeks of ultrasonic irradiation, the following day, sacrificed, a section of the femoral condyle of the dog's knee was prepared, and Mankin's evaluation method was used [Mankin et al. J Bone and Joint Surg 53-A, 523-537 (1971)] [Lafeber et al. Am J Pathol 140, 1421-1429 (1992)].
- tissue sections were stained with safranin monochrome, and evaluated under a light microscope on the three-point scale shown in Table 1 for the three items of cartilage tissue structure, chondrocyte distribution and density, and safranin mono-O staining. .
- the results are shown in FIG.
- MMP activity in synovial fluid can be measured by the following methods: TN0113 (substrate for MMP-1 assay, TNO Corporation), TNO003 (for MMP-3 assay) Substrate, manufactured by TNO), TNO013 (substrate for measuring MP-13, manufactured by TNO), and using its fluorescence curve and known MMP, the MMP concentration in synovial fluid ( nM).
- the activity of MMP-1, MMP-3, and MMP-13 in the ultrasonic irradiation group tended to decrease compared to the comparative example (P20. 0, 0. 09, ⁇ . 05).
- the use of an ultrasonic irradiation device reduces the increase in MMP activity associated with joint disease and improves the tissue score. Therefore, while staying at home, it is possible to repair tissue degeneration and treat a joint disease with a short period of about 20 minutes of ultrasonic irradiation.
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Radiology & Medical Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Surgical Instruments (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP02738808A EP1400212A4 (en) | 2001-06-26 | 2002-06-26 | APPARATUS AND METHOD FOR TREATING JOINT DISEASES |
US10/415,470 US20040015105A1 (en) | 2001-06-26 | 2002-06-26 | Apparatus and method for treating joint disease |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2001-192629 | 2001-06-26 | ||
JP2001192629A JP4660024B2 (ja) | 2001-06-26 | 2001-06-26 | Mmp活性低下装置及び方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2003000147A1 true WO2003000147A1 (fr) | 2003-01-03 |
Family
ID=19031058
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2002/006438 WO2003000147A1 (fr) | 2001-06-26 | 2002-06-26 | Appareil et methode de traitement de maladies des articulations |
Country Status (4)
Country | Link |
---|---|
US (1) | US20040015105A1 (ja) |
EP (1) | EP1400212A4 (ja) |
JP (1) | JP4660024B2 (ja) |
WO (1) | WO2003000147A1 (ja) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7914470B2 (en) * | 2001-01-12 | 2011-03-29 | Celleration, Inc. | Ultrasonic method and device for wound treatment |
US8235919B2 (en) * | 2001-01-12 | 2012-08-07 | Celleration, Inc. | Ultrasonic method and device for wound treatment |
JP2005052523A (ja) * | 2003-08-07 | 2005-03-03 | Teijin Ltd | 椎間板ヘルニア自然退縮を促進する超音波照射装置 |
KR100537343B1 (ko) * | 2004-10-01 | 2005-12-19 | 주식회사 듀플로젠 | 관절염 치료용 초음파 장치 |
JP4533758B2 (ja) * | 2005-01-17 | 2010-09-01 | 帝人ファーマ株式会社 | 腎疾患治療装置 |
US8491521B2 (en) * | 2007-01-04 | 2013-07-23 | Celleration, Inc. | Removable multi-channel applicator nozzle |
US20090177123A1 (en) * | 2007-12-28 | 2009-07-09 | Celleration, Inc. | Methods for treating inflammatory disorders |
US20100022919A1 (en) * | 2008-07-22 | 2010-01-28 | Celleration, Inc. | Methods of Skin Grafting Using Ultrasound |
US9597099B2 (en) | 2013-07-29 | 2017-03-21 | Covidien Lp | Energy-based treatment methods for refractory gout |
AU2014355072A1 (en) | 2013-11-26 | 2016-06-02 | Alliqua Biomedical, Inc. | Systems and methods for producing and delivering ultrasonic therapies for wound treatment and healing |
CN112439132B (zh) * | 2019-08-28 | 2023-03-28 | 延世大学原州产学合作团 | 使用陶瓷组合物和低强度超声波改善关节炎的装置 |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6247359A (ja) * | 1985-08-28 | 1987-03-02 | アロカ株式会社 | 骨用超音波刺激装置 |
WO1993016652A1 (en) * | 1992-02-25 | 1993-09-02 | Young Michael John R | Apparatus for ultrasonic therapeutic treatment |
WO1993021889A1 (en) * | 1990-09-11 | 1993-11-11 | Unger Evan C | Method for hyperthermic potentiation of tissue |
US5273033A (en) | 1991-09-19 | 1993-12-28 | Murray Electronics Associates Limited Partnership | Electrical stimulation for treatment of osteoarthritis |
US5545124A (en) * | 1993-05-07 | 1996-08-13 | Siemens Aktiengesellschaft | Method for alleviating the sensation of pain |
WO1998057707A1 (de) * | 1997-06-17 | 1998-12-23 | Ferton Holding | Medizinisches instrument zur behandlung von biologischem gewebe |
WO1999047208A1 (en) * | 1998-03-17 | 1999-09-23 | Exogen, Inc. | Apparatus and method for mounting an ultrasound transducer |
US5972880A (en) | 1996-03-07 | 1999-10-26 | Arthro Lab Inc. | Method of treatment of osteoarthritis with interleuken-1 receptor antagonist |
WO2000047125A1 (en) | 1999-02-13 | 2000-08-17 | Tissuemed Limited | Optical apparatus |
US6174915B1 (en) | 1997-03-25 | 2001-01-16 | Agouron Pharmaceuticals, Inc. | Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR8107560A (pt) * | 1981-11-19 | 1983-07-05 | Luiz Romariz Duarte | Estimulacao ultra-sonica da consolidacao de fraturas osseas |
US5186162A (en) * | 1988-09-14 | 1993-02-16 | Interpore Orthopaedics, Inc. | Ultrasonic transducer device for treatment of living tissue and/or cells |
US5003965A (en) * | 1988-09-14 | 1991-04-02 | Meditron Corporation | Medical device for ultrasonic treatment of living tissue and/or cells |
US5211160A (en) * | 1988-09-14 | 1993-05-18 | Interpore Orthopaedics, Inc. | Ultrasonic orthopedic treatment head and body-mounting means therefor |
US5789434A (en) * | 1994-11-15 | 1998-08-04 | Bayer Corporation | Derivatives of substituted 4-biarylbutyric acid as matrix metalloprotease inhibitors |
US5520612A (en) * | 1994-12-30 | 1996-05-28 | Exogen, Inc. | Acoustic system for bone-fracture therapy |
US5556372A (en) * | 1995-02-15 | 1996-09-17 | Exogen, Inc. | Apparatus for ultrasonic bone treatment |
US5730705A (en) * | 1995-06-12 | 1998-03-24 | Talish; Roger J. | Ultrasonic treatment for bony ingrowth |
ES2385305T3 (es) * | 1997-02-06 | 2012-07-20 | Exogen, Inc. | Kit para estimular el crecimiento del cartílago |
US7789841B2 (en) * | 1997-02-06 | 2010-09-07 | Exogen, Inc. | Method and apparatus for connective tissue treatment |
US5904659A (en) * | 1997-02-14 | 1999-05-18 | Exogen, Inc. | Ultrasonic treatment for wounds |
DK0975391T3 (da) * | 1997-04-18 | 2004-06-07 | Exogen Inc | Apparat til ultralydsknoglebehandling |
US5804581A (en) * | 1997-05-15 | 1998-09-08 | Bayer Corporation | Inhibition of matrix metalloproteases by substituted phenalkyl compounds |
EP1072241A4 (en) * | 1999-02-15 | 2004-04-14 | Teijin Ltd | JOINT ACCESSORY |
CA2442047A1 (en) * | 2002-01-18 | 2003-07-31 | Teijin Limited | Method of treating osteochondrosis and apparatus for treating osteochondrosis |
-
2001
- 2001-06-26 JP JP2001192629A patent/JP4660024B2/ja not_active Expired - Fee Related
-
2002
- 2002-06-26 US US10/415,470 patent/US20040015105A1/en not_active Abandoned
- 2002-06-26 EP EP02738808A patent/EP1400212A4/en not_active Ceased
- 2002-06-26 WO PCT/JP2002/006438 patent/WO2003000147A1/ja active Application Filing
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6247359A (ja) * | 1985-08-28 | 1987-03-02 | アロカ株式会社 | 骨用超音波刺激装置 |
WO1993021889A1 (en) * | 1990-09-11 | 1993-11-11 | Unger Evan C | Method for hyperthermic potentiation of tissue |
US5273033A (en) | 1991-09-19 | 1993-12-28 | Murray Electronics Associates Limited Partnership | Electrical stimulation for treatment of osteoarthritis |
WO1993016652A1 (en) * | 1992-02-25 | 1993-09-02 | Young Michael John R | Apparatus for ultrasonic therapeutic treatment |
US5545124A (en) * | 1993-05-07 | 1996-08-13 | Siemens Aktiengesellschaft | Method for alleviating the sensation of pain |
US5972880A (en) | 1996-03-07 | 1999-10-26 | Arthro Lab Inc. | Method of treatment of osteoarthritis with interleuken-1 receptor antagonist |
US6174915B1 (en) | 1997-03-25 | 2001-01-16 | Agouron Pharmaceuticals, Inc. | Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses |
WO1998057707A1 (de) * | 1997-06-17 | 1998-12-23 | Ferton Holding | Medizinisches instrument zur behandlung von biologischem gewebe |
WO1999047208A1 (en) * | 1998-03-17 | 1999-09-23 | Exogen, Inc. | Apparatus and method for mounting an ultrasound transducer |
WO2000047125A1 (en) | 1999-02-13 | 2000-08-17 | Tissuemed Limited | Optical apparatus |
Non-Patent Citations (1)
Title |
---|
See also references of EP1400212A4 * |
Also Published As
Publication number | Publication date |
---|---|
JP2003000611A (ja) | 2003-01-07 |
EP1400212A1 (en) | 2004-03-24 |
JP4660024B2 (ja) | 2011-03-30 |
EP1400212A4 (en) | 2009-12-02 |
US20040015105A1 (en) | 2004-01-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7189209B1 (en) | Method for using acoustic shock waves in the treatment of a diabetic foot ulcer or a pressure sore | |
KR100537343B1 (ko) | 관절염 치료용 초음파 장치 | |
US7470240B2 (en) | Pressure pulse/shock wave therapy methods and an apparatus for conducting the therapeutic methods | |
Rawool et al. | Power Doppler assessment of vascular changes during fracture treatment with low‐intensity ultrasound | |
TWI507228B (zh) | 非侵入性破壞脂肪組織並加速脂質代謝之系統 | |
US20220000509A1 (en) | Ultrasound Device for Use with Synthetic Cavitation Nuclei | |
Rassweiler et al. | Progress in lithotriptor technology | |
MXPA05003785A (es) | Regulacion de la expresion genica del colageno de tipo ii usando senales electricas y electromagneticas especificas y selectivas. | |
WO2003000147A1 (fr) | Appareil et methode de traitement de maladies des articulations | |
MXPA05003259A (es) | Regulacion de la expresion del gen del agrecano utilizando senales electricas y electromagneticas especificas y selectivas. | |
MXPA05013493A (es) | Regulacion de expresion de gen de metaloproteinasa de la matriz usando senales electricas y electromagneticas especificas y selectivas. | |
JP4533758B2 (ja) | 腎疾患治療装置 | |
KR102040165B1 (ko) | 초음파 및 미세전류를 이용한 치료 장치 | |
Warden et al. | Can conventional therapeutic ultrasound units be used to accelerate fracture repair? | |
WO2003061492A1 (fr) | Methode de traitement de l'osteochondrite et appareil de traitement de l'osteochondrite | |
RU2468839C2 (ru) | Способ лечения воспалительно-дегенеративных патологий суставов | |
WO2015041254A1 (ja) | 血管内皮機能障害を処置する装置、血管内皮機能障害を処置する方法ならびにPLCγ1、ERK5またはERK1/2の活性化制御方法 | |
CA2824264C (en) | Method and device for treating osteoarthritis noninvasively | |
JP2005304918A (ja) | 創傷治療装置 | |
US20090082703A1 (en) | Method and apparatus for the treatment of tendon abnormalities | |
US20060293616A1 (en) | Disc herniation treating method and apparatus | |
Jabbary | Effect of high intensity focused ultrasound on neural compound action potential: An in vitro study | |
WO2024030212A1 (en) | Reversal of cellular senescence by treatment with low frequency ultrasound | |
Sonnenschein | Ultrasoundwave treatment of chronic disorders of the locomotor system | |
CN116096456A (zh) | 用于促进治愈肺部或血栓形成疾病或抑制其发展的方法和系统 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2002738808 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10415470 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 2002738808 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |